Case report of successful use of VP-16 in nasopharyngeal carcinoma

D. Daghistani, Joanna A Davis, S. Toledano

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

We report the use of VP-16 as a single agent for the treatment of nasopharyngeal carcinoma. Our patient, a 16-year-old Black Haitian male, had complete clinical and radiographic response to VP-16. The remission continued for 14 months. The patient experienced minimal toxicity. We believe that the good response, excellent compliance, and minimal toxicity experienced by our patient should encourage more trials of VP-16 as upfront therapy for patients with nasopharygeal carcinoma.

Original languageEnglish
Pages (from-to)168-169
Number of pages2
JournalMedical and Pediatric Oncology
Volume17
Issue number2
StatePublished - Jan 1 1989

Fingerprint

Etoposide
Compliance
Carcinoma
Nasopharyngeal carcinoma
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pediatrics, Perinatology, and Child Health

Cite this

Daghistani, D., Davis, J. A., & Toledano, S. (1989). Case report of successful use of VP-16 in nasopharyngeal carcinoma. Medical and Pediatric Oncology, 17(2), 168-169.

Case report of successful use of VP-16 in nasopharyngeal carcinoma. / Daghistani, D.; Davis, Joanna A; Toledano, S.

In: Medical and Pediatric Oncology, Vol. 17, No. 2, 01.01.1989, p. 168-169.

Research output: Contribution to journalArticle

Daghistani, D, Davis, JA & Toledano, S 1989, 'Case report of successful use of VP-16 in nasopharyngeal carcinoma', Medical and Pediatric Oncology, vol. 17, no. 2, pp. 168-169.
Daghistani D, Davis JA, Toledano S. Case report of successful use of VP-16 in nasopharyngeal carcinoma. Medical and Pediatric Oncology. 1989 Jan 1;17(2):168-169.
Daghistani, D. ; Davis, Joanna A ; Toledano, S. / Case report of successful use of VP-16 in nasopharyngeal carcinoma. In: Medical and Pediatric Oncology. 1989 ; Vol. 17, No. 2. pp. 168-169.
@article{3b1b7e6d20c34ea9a8020710780f3de4,
title = "Case report of successful use of VP-16 in nasopharyngeal carcinoma",
abstract = "We report the use of VP-16 as a single agent for the treatment of nasopharyngeal carcinoma. Our patient, a 16-year-old Black Haitian male, had complete clinical and radiographic response to VP-16. The remission continued for 14 months. The patient experienced minimal toxicity. We believe that the good response, excellent compliance, and minimal toxicity experienced by our patient should encourage more trials of VP-16 as upfront therapy for patients with nasopharygeal carcinoma.",
author = "D. Daghistani and Davis, {Joanna A} and S. Toledano",
year = "1989",
month = "1",
day = "1",
language = "English",
volume = "17",
pages = "168--169",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Case report of successful use of VP-16 in nasopharyngeal carcinoma

AU - Daghistani, D.

AU - Davis, Joanna A

AU - Toledano, S.

PY - 1989/1/1

Y1 - 1989/1/1

N2 - We report the use of VP-16 as a single agent for the treatment of nasopharyngeal carcinoma. Our patient, a 16-year-old Black Haitian male, had complete clinical and radiographic response to VP-16. The remission continued for 14 months. The patient experienced minimal toxicity. We believe that the good response, excellent compliance, and minimal toxicity experienced by our patient should encourage more trials of VP-16 as upfront therapy for patients with nasopharygeal carcinoma.

AB - We report the use of VP-16 as a single agent for the treatment of nasopharyngeal carcinoma. Our patient, a 16-year-old Black Haitian male, had complete clinical and radiographic response to VP-16. The remission continued for 14 months. The patient experienced minimal toxicity. We believe that the good response, excellent compliance, and minimal toxicity experienced by our patient should encourage more trials of VP-16 as upfront therapy for patients with nasopharygeal carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=0024599138&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024599138&partnerID=8YFLogxK

M3 - Article

VL - 17

SP - 168

EP - 169

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 2

ER -